Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerAI sign LanguageOpen
VIPCreated with Sketch.

Lutetium-177 PSMA radioligand therapy for metastatic castration resistant prostate cancer in Germany: population-based data with multicenter validation from 2016 to 2020

Luka Flegar,S. Thoduka,Damiano Librizzi,M. Luster,Aristeidis Zacharis,Hendrik Heers,N. Eisenmenger,Hojjat Ahmadzadehfar,M. Eiber,W. Weber,Christer Groeben,Johannes Huber

Nuklearmedizin-nuclear Medicine（2023）

Cited 0|Views10
No score
Abstract
Ziel/Aim To investigate the adoption and current trends of Lutetium-177 PSMA radioligand therapy (RLT) for metastatic castration-resistant prostate cancer (mCRPC) in Germany.
More
Translated text
Key words
resistant prostate cancer,prostate cancer,psma radioligand therapy,metastatic castration,population-based
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined